Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review

References

• Amacher DE. (2014). Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers 19:541–52
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. (2007). The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with nafld. Hepatology 45:846–54
   PubMed Web of Science ®Google Scholar
• Aqel, B, Langlais P, Vargas HE, et al. (2014). Prospective assessment of the abundance of drug metabolizing enzymes in the p450 pathway in patients with non alcoholic fatty liver disease (NAFLD). Hepatology 60:759A
   PubMed Web of Science ®Google Scholar
• Balanescu P, Ladaru A, Balanescu E, et al. (2014). Systemic sclerosis biomarkers discovered using mass-spectrometry-based proteomics: a systematic review. Biomarkers 19:345–55
   PubMed Web of Science ®Google Scholar
• Bell LN, Saxena R, Mattar SG, et al. (2011). Utility of formalin-fixed, paraffin-embedded liver biopsy specimens for global proteomic analysis in nonalcoholic steatohepatitis. Proteomics Clin Appl 5:397–404
   PubMed Web of Science ®Google Scholar
• Cardellini M, Gentileschi P, Davato F, et al. (2011). Molecular basis of nonalcoholic fatty liver disease (N AFLD) in obese patients with or without glucose intolerance. Diabetologia 54:S285
   Web of Science ®Google Scholar
• Charlton M, Viker K, Krishnan A, et al. (2009). Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 49:1375–84
   PubMed Web of Science ®Google Scholar
• Choe YG, Jin W, Cho YK, et al. (2013). Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J Gastroenterol Hepatol 28:678–83
   PubMed Web of Science ®Google Scholar
• Del Galdo F, Shaw MA, Jimenez SA. (2010). Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. Am J Pathol 177:1638–46
   PubMed Web of Science ®Google Scholar
• Gaens KHJ, Niessen PMG, Rensen SS, et al. (2011). Increased endogenous formation of n(epsilon)-(carboxymethyl)lysine in fatty liver induces inflammatory markers in an in vitro model of hepatic steatosis. Diabetologia 54:S286
   Web of Science ®Google Scholar
• Gaens KHJ, Niessen PMG, Rensen SS, et al. (2012). Endogenous formation of n(epsilon)-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol 56:647–55
   PubMed Web of Science ®Google Scholar
• Gray J, Chattopadhyay D, Beale GS, et al. (2009). A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 9:271
   PubMed Web of Science ®Google Scholar
• Hoque M, Rentero C, Cairns R, et al. (2014). Annexins – scaffolds modulating pkc localization and signaling. Cell Signal 26:1213–25
   PubMed Web of Science ®Google Scholar
• Huang SC, Yang YJ. (2013). Serum retinol-binding protein 4 is independently associated with pediatric nafld and fasting triglyceride level. J Pediatr Gastroenterol Nutr 56:145–50
   PubMed Web of Science ®Google Scholar
• Kim BJ, Kim BS, Kang JH. The association between serum ferritin level, microalbuminuria and non-alcoholic fatty liver disease in non-diabetic, non-hypertensive men. Clin Exp Hypertens 2014;36:380–5
   Google Scholar
• Lackner C. (2011). Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Expert Rev Gastroenterol Hepatol 5:223–31
   PubMed Web of Science ®Google Scholar
• Lindner SA, Flint MS, Stewart NA, et al. (2011). Proteonomic analysis of recurrent nonalcoholic steatohepatitis in liver transplantation. Hepatology 54:692A
   Web of Science ®Google Scholar
• Michail S, Frey MR, Fanter R, et al. (2013). Altered gut microbial energy and metabolism in children with non alcoholic fatty liver disease. Gastroenterology 144:S30
   PubMed Web of Science ®Google Scholar
• Miller M, Ferguson M, Dillon JF. (2009). ITRAQ technology for the discovery of biomarkers in human NAFLD. Hepatology 50:1187A
   Web of Science ®Google Scholar
• Miller M, Jafferbhoy H, Crowther D, et al. (2011). Novel non-invasive scoring system for the detection of nash from a nafld population. Hepatology 54:1113A
   PubMed Web of Science ®Google Scholar
• Miller MH, Walsh SV, Atrih A, et al. (2014). The serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 29:1839–47
   PubMed Web of Science ®Google Scholar
• Mischak H, Allmaier G, Apweiler R, et al. (2010). Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2:46ps42
   PubMed Web of Science ®Google Scholar
• Neuman MG, Cohen LB, Nanau RM. (2014). Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol 28:607–14
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Charlotte F, et al. (2006). Diagnostic value of biochemical markers (NASHtest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:34
   PubMed Web of Science ®Google Scholar
• Rodriguez-Suarez E, Duce AM, Caballeria J, et al. (2010). Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl 4:362–71
   PubMed Web of Science ®Google Scholar
• Samy W, Hassanian MA. (2011). Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol 12:80–5
   PubMedGoogle Scholar
• Sarsby J, Martin NJ, Lalor PF, et al. (2014). Top-down and bottom-up identification of proteins by liquid extraction surface analysis mass spectrometry of healthy and diseased human liver tissue. J Am Soc Mass Spectrom 25:1953–61
   PubMed Web of Science ®Google Scholar
• Su W, Wang Y, Jia X, et al. (2014). Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 111:11437–42
   PubMed Web of Science ®Google Scholar
• Theodorakis JL, Vuppalanchi R, You J, et al. (2009). Mass spectrometry-based serum proteomics approach to biomarker discovery for non-invasive diagnostics of non-alcoholic steatohepatitis (nash). Gastroenterology 136:A845–6
   Web of Science ®Google Scholar
• Trak-Smayra V, Dargere D, Noun R, et al. (2009). Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 58:825–32
   PubMed Web of Science ®Google Scholar
• Uchida K, Suzuki H, Meno K, et al. (2011). Liver proteome expression profile in diabetic obese subjects. Hepatol Int 5:17
   Google Scholar
• Ulukaya E, Yilmaz Y, Moshkovskii S, et al. (2009). Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol 44:1471–6
   PubMed Web of Science ®Google Scholar
• Valle A, Catalan V, Rodriguez A, et al. (2012a). Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects. Liver Int 32:951–61
   PubMed Web of Science ®Google Scholar
• Valle A, Catalan V, Rodriguez A, et al. (2012b). Liver proteome expression profile in diabetic obese subjects. FEBS Journal 279:212
   Web of Science ®Google Scholar
• van Genderen HO, Kenis H, Hofstra L, et al. (2008). Extracellular annexin A5: functions of phosphatidylserine-binding and two-dimensional crystallization. Biochim Biophys Acta 1783:953–63
   PubMed Web of Science ®Google Scholar
• Xin YN, Geng N, Lin ZH, et al. (2014). Serum complement c3f and fibrinopeptide a are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in qingdao twins. PLoS One 9:e108132
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Baranova A, Ziegler K, et al. (2005). A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42:665–74
   PubMed Web of Science ®Google Scholar
• Yu C, Xu C, Xu L, et al. (2012). Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 56:241–7
   PubMed Web of Science ®Google Scholar